Use of clozapine in an adolescent with refractory first-episode psychosis and neutropenia

Journal of Clinical Psychopharmacology

Volumn 30, Issue 3, 2010, Pages 336-338

  Ragonnet, Laure ^a   Abadie, Pascale ^a   Dollfus, Sonia ^a,b  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE CAEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALIMEMAZINE; AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMIC ACID; CLOZAPINE; CYAMEMAZINE; HALOPERIDOL; LITHIUM SALT; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; RISPERIDONE; VALPROMIDE; ZUCLOPENTHIXOL;

ADOLESCENT; AGITATION; AGRANULOCYTOSIS; AUTISM; CASE REPORT; CONCENTRATION LOSS; DRUG RESPONSE; DRUG WITHDRAWAL; DYSTONIA; ERYTHROCYTE; FAMILY HISTORY; HEMATOLOGIC DISEASE; HUMAN; INTESTINE OBSTRUCTION; IRRITABILITY; LETTER; LEUKOCYTE COUNT; LONELINESS; MALE; METABOLIC DISORDER; MYOCARDITIS; NEUTROPENIA; NEUTROPHIL; NEUTROPHIL COUNT; PRIORITY JOURNAL; PSYCHOSIS; PSYCHOSOCIAL WITHDRAWAL; RECURRENT DISEASE; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; THROMBOCYTE; WEIGHT GAIN;

ADOLESCENT; CLOZAPINE; HUMANS; MALE; NEUTROPENIA; PSYCHOTIC DISORDERS;

EID: 77952367635     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181dbfc22     Document Type: Letter

References (14)

1. Gogtay N, Rapoport J. Clozapine use in children and adolescents. Expert Opin Pharmacother. 2008;9(3):459-465.
2. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and Bhigh-dose[olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry. 2008;63:524-529.
3. Agid O, Remington G, Kapur S, et al. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol. 2007;27(4):369-373.
4. Schulte PF. Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring. Ann Pharmacotherapy. 2009;40(4):683-688.
5. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry. 1996;53(12):1090-1097.
6. Gerbino-Rosen G, Roofeh D, Tompkins DA, et al. Hematological adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatry. 2005;44(10):1024-1031.
7. Woerner MG, Robinson DG, Alvir JM, et al. Clozapine as a first treatment for schizophrenia. Am J Psychiatry. 2003;160(8):1514-1516.
8. Kim Y, Kim BN, Cho SC, et al. Long-term sustained benefits of clozapine treatment in refractory early onset schizophrenia: a retrospective study in Korean children and adolescents. Hum Psychopharmacol. 2008;23:715-717.
9. Whiskey E, Taylor D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs. 2007;21(1):25-35.
10. Sedky K, Lippmann S. Psychotropic medications and leukopenia. Curr Drug Targets. 2006;7(9):1191-1194.
11. Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol Clin Exp. 2008;23:27-41.
12. Porter R, Mohamed A. Diurnal variation of neutropenia during clozapine treatment. Int J Neuropsychopharmacol. 2006;9(3):373-374.
13. Esposito D, Chouinard G, Hardy P, et al. Successful initiation of clozapine treatment despite morning pseudoneutropenia. Int J Neuropsychopharmacol. 2006;9(4):489-491.
14. Dunk LR, Annan LJ, Andrews CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry. 2006;188(3):255-263.